SLDB - NASDAQ

Solid Biosciences Inc.

Solid Biosciences Inc.

SLDBยทNASDAQ

$6.85

+4.1%
HealthcareBiotechnology

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$533.68M
EPS-1.9900
P/E Ratio-3.44
Earnings Date08/11/2026
Solid Biosciences Inc.

Solid Biosciences Inc. Fair Value Envelope

SLDB ยท NASDAQ

Our analysis suggests that SLDB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.85, this represents a potential HIDDEN relative to our calculated worth for Solid Biosciences Inc..

HIDDEN
Intrinsic Value
Current Price: $6.85

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$134.9M
+ Cash & Equivalents$59.9M
Firm Value-$75.0M
- Debt$21.2M
Equity Value-$96.1M
/ Shares Outstanding77,869,071B
DCF Value-$1
OVERVALUED BY 118%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$78.1M
-$39.1M
-$19.5M
-$9.8M
-$4.9M
-$2.4M
-$1.2M
-$610.5K
-$305.3K
-$152.6K
Maintenance CapEx
-$115.3K
-$57.7K
-$28.8K
-$14.4K
-$7.2K
-$3.6K
-$1.8K
-$901
-$450
-$225
Owner Earnings
-$78.3M
-$39.1M
-$19.6M
-$9.8M
-$4.9M
-$2.4M
-$1.2M
-$611.4K
-$305.7K
-$152.9K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$72.5M
-$33.5M
-$15.5M
-$7.2M
-$3.3M
-$1.5M
-$713.5K
-$330.3K
-$152.9K
-$70.8K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your SLDB research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.